Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

23.4%

44 terminated/withdrawn out of 188 trials

Success Rate

74.4%

-12.1% vs industry average

Late-Stage Pipeline

43%

80 trials in Phase 3/4

Results Transparency

56%

72 of 128 completed trials have results

Key Signals

2 recruiting72 with results35 terminated9 withdrawn

Enrollment Performance

Analytics

Phase 3

57(34.1%)

Phase 2

45(26.9%)

Phase 1

33(19.8%)

Phase 4

23(13.8%)

N/A

7(4.2%)

Early Phase 1

2(1.2%)

167Total

Phase 3(57)

Phase 2(45)

Phase 1(33)

Phase 4(23)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (188)

Showing 20 of 188 trials

NCT01241383Phase 2Completed

Effect of Bosentan in Scleroderma Renal Crisis

Role: collaborator

NCT04175600Phase 3Active Not Recruiting

A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension

Role: lead

NCT04273945Phase 3Active Not Recruiting

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

Role: lead

NCT03492177Phase 2Active Not Recruiting

A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension

Role: lead

NCT05179876Phase 3Recruiting

A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option

Role: lead

NCT04914247Unknown

Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease

Role: lead

NCT02932410Phase 3Completed

A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

Role: lead

NCT00777985Phase 2Completed

Preventive Effects of Bosentan on the Systemic Cardiovascular Consequence of Sleep Apnea

Role: collaborator

NCT03904693Phase 3Completed

Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)

Role: lead

NCT02325362Phase 2Completed

Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation

Role: collaborator

NCT01106014Phase 3Completed

Selexipag (ACT-293987) in Pulmonary Arterial Hypertension

Role: lead

NCT00993408Phase 2Completed

Study of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH)

Role: lead

NCT03105479Phase 2Terminated

Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD)

Role: lead

NCT03187678Phase 3Completed

Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension

Role: lead

NCT04271475Phase 3Terminated

A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

Role: lead

NCT03359291Phase 1Completed

Clinical Study to Investigate the Effect of Macitentan on the Concentrations of Rosuvastatin in the Blood of Healthy Male Subjects

Role: lead

NCT03215966Phase 1Completed

A Study to Compare the Macitentan-tadalafil Fixed Dose Combination Tablet Relative to the Concomitant Administration of the Reference Tablets of Macitentan and Tadalafil in Healthy Subjects

Role: lead

NCT02309463Withdrawn

Correlation of LONGterm Wrist ACTigraphy Recorded Physical Performance & 6-minute Walk Distance in Patients With Pulmonary Arterial Hypertension

Role: lead

NCT03496506Phase 1Completed

A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male Subjects

Role: lead

NCT01346930Phase 2Withdrawn

Safety and Tolerability Study of Macitentan in Patients With Idiopathic Pulmonary Fibrosis

Role: lead